Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-151 is a potent, irreversible, and selective small molecule inhibitor of the stimulator of interferon genes (STING) protein. It acts by covalently binding to the transmembrane cysteine residue at position 91 (Cys91) of STING, thereby blocking its palmitoylation and clustering—two essential steps for STING signaling. This inhibition prevents downstream activation processes such as type I interferon response and pro-inflammatory cytokine production. H-151 has demonstrated significant anti-inflammatory and antiviral effects in preclinical models by reducing cytokine signaling. It is being investigated primarily for autoinflammatory diseases where aberrant STING activation plays a role[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H-151.